Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Akash Sabarwal

Has grant

Scientist/Faculty

Boston Children's Hospital

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Recent Grants

Grant: Open

Bridge Funding

Open Date: 2025-07-01

Close Date: 2028-06-01

Grant: Open

Investigatorship Award

Open Date: 2023-01-01

Close Date: 2027-12-01

Grant: Close

Targeting AXL to effectively inhibit c-Met and to overcome therapeutic-resistance in Renal Cancer

Open Date: 2022-09-01

Close Date: 2023-09-01

Articles (9)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Harsh Goel

Research Scientist-I

All India Institute of Medical Sciences

View details

Yuzuru Sasamoto

Assistant Professor

University of Washington

UNITED STATES

View details

Dongwon Lee

Assistant Professor

Boston Children's Hospital

UNITED STATES

View details

Soumitro Pal

Associate Professor

Harvard University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Akash Sabarwal

Research Interests

Explore related searches

Recent Grants

Articles (9)

Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities

Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress.

Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies.

A comprehensive review of anti-cancer mechanisms of polyphenol honokiol and nano carrier-based approaches to enhance its therapeutic potential

AXL signaling in cancer: from molecular insights to targeted therapies.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

Aminoacyl‐tRNA synthetase – a molecular multitasker

Targeting AXL can effectively inhibit c-Met-induced therapeutic resistance in renal cancer

Collaborators (4)

Harsh Goel

Yuzuru Sasamoto

Dongwon Lee

Soumitro Pal

Make your next move.